Market Overview
The Global Common Warts Treatment Market is expected to reach at a high CAGR during the forecast period 2026-2033.
Common warts, commonly known as verruca vulgaris, are benign skin growths that are caused by the human papillomavirus (HPV). They are often tiny, raised, rough, and cauliflower-like in appearance. Common warts can appear on any area of the body, although they are most usually found on the hands, fingers, and around the nails.
The global common warts treatment market has grown significantly in recent years and is projected to continue on its upward trend. The market is undergoing a transformational period, influenced by several significant trends such increasing adoption towards immunotherapy and cryotherapy due to its availability of easy-to-use cryotherapy kits for self-treatment.
Market Scope
| Metrics | Details |
| CAGR | High |
| Size Available for Years | 2023-2033 |
| Forecast Period | 2026-2033 |
| Data Availability | Value (US$ Mn) |
| Segments Covered | Treatment Type, Age Group, Sales Channel, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For More Details on this report - Request Sample
Market Dynamics
The increasing number of organ transplant
The market for common warts treatment is expected to grow as the number of organ transplants increases. Owing to their immunocompromised state, organ transplant recipients are more susceptible to developing warts such as common warts caused by human papillomavirus (HPV). After transplantation, the chance of acquiring cutaneous tumors is substantially higher than in the immunocompetent population. The prevalence of warts increases with the duration of immunosuppression, reaching 50-90% in patients more than 4-5 years after transplantation.
The development of warts is also affected by the immunosuppressant used and the time interval between transplants. Furthermore, cutaneous common warts (verruca vulgaris) are a common complication following kidney transplantation. According to a report published in Baishideng Publishing Group in 2023, the incidence of warts was 28% in a study of 60 children and adolescents with KT, with increasing prevalence with time after kidney transplantation. As a result of the factors listed above, the market is expected to grow throughout the forecast period.
Restraint
Cosmetics and stigma concerns about common warts arise from the social stigma associated with visible skin disorders such as common warts, which may cause persons uncomfortable or self-conscious. This stigma is sometimes caused by misconceptions about the condition and might discourage people from seeking medical treatment.
Moreover, concerns about scars or skin damage from treatments like cryotherapy or surgical removal can also prevent people from seeking help, especially if the warts are in prominent areas. These psychological and cosmetic factors, along with anxiety about painful treatment methods, can prevent people from treating common warts thereby restraining the market over the forecast period.
Market Segment Analysis
The global common warts treatment market is segmented based on treament type, age group, sales channel and region.
The drug therapy segment accounted for approximately 32.2% of the common warts treatment market share
The drug therapy segment is expected to dominate the global common warts treatment market accounted for 54.2% market share, due to its accessibility, convenience, and non-invasive nature, which makes it a popular choice, particularly for mild to moderate cases. Drug therapies, which include topical creams, solutions, and gels containing active ingredients such as salicylic acid and Imiquimod, offer patients an effective way of treating common warts while causing little impact on their everyday lives.
Furthermore, salicyclic acid solutions is most commonly used drug therapy for common warts, as this solution forms a thin layer over the wart. It works as keratolytic therapy that works by chemically debriding the wart of excess keratin and inducing an inflammatory response. Moreover, it is readily available without prescription too in pharmacies.
Market Geographical Share
North America accounted for approximately 37.4% of the market share
North America is estimated to hold about 37.4% of the total market share throughout the forecast period, owing to the increasing number of prevalence of HPV and associated cancer with this HPV infection, growing awareness about the warts and launch of new products will drive this region further during the forecast period.
Moreover, HPV is responsible for around 37,000 of these cancer cases. Cervical cancer is the most common HPV-linked disease in women, whereas oropharyngeal cancers, which include malignancies in the throat's posterior region, including the base of the tongue and tonsils, are the most common in men. Thus, owing to above factors the region is expected to grow over the forecast period.
Market Major Companies
The major global players in the common warts treatment market include Prestige Consumer Healthcare Inc., STADA Arzneimittel AG, Bausch Health Companies Inc., Pfizer Inc., Verrica Pharmaceuticals, GlaxoSmithKline plc, Taro pharmaceutical Industries Ltd., Orgenesis biotech company, Teva pharmaceutical industries Ltd., Novan Inc. and among others.
Key Developments
- May 2026: Verrica Pharmaceuticals reported that its global Phase 3 COVE-2 trial for YCANTH® (VP-102) in common warts surpassed 50% patient enrollment. The company highlighted continued advancement of its proprietary cantharidin-based drug-device technology aimed at becoming the first FDA-approved prescription therapy for common warts.
- February 2026: Shionogi & Co., Ltd. and Torii Pharmaceutical Co., Ltd. commercially launched YCANTH® topical solution 0.71% in Japan. The launch strengthened cantharidin-based dermatology innovation and expanded physician-administered viral skin treatment technologies across the Asia-Pacific region.
- January 2026: Verrica Pharmaceuticals announced the first patient dosing in its global Phase 3 program evaluating YCANTH® (VP-102) for common warts treatment. The study followed positive Phase 2 COVE-1 data, where the therapy demonstrated meaningful complete wart clearance rates using its precision topical applicator platform.
Why Purchase the Report?
- To visualize the global common warts treatment market segmentation based on treatment type, age group, sales channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of common warts treatment market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping is available in excel consisting of key products of all the major players.
The global common warts treatment market report would provide approximately 61 tables, 57 figures and 195 Pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
